ACCELRYS, INC. 4
4 · ACCELRYS, INC. · Filed Sep 27, 2013
Insider Transaction Report
Form 4
ACCELRYS, INC.ACCL
HAHN MATHEW A
VP, Research and Development
Transactions
- Sale
Common stock
2013-09-25$9.96/sh−6,772$67,417→ 0 total - Sale
Common stock
2013-09-27$9.95/sh−200$1,990→ 0 total - Sale
Common stock
2013-09-26$9.98/sh−10,903$108,773→ 0 total
Footnotes (1)
- [F1]Pursuant to his 10b5-1 plan, Dr. Hahn disposed of common stock acquired through the sale of Scitegic to Accelrys in 2004.